| 1. IDENTIFICATION & BASIC DESCRIPTION |
|
Cohort name
|
| |
Golestan Cohort Study
|
|
Country
|
| |
|
|
Please provide any other information on the cohort location/s if needed
|
| |
Golestan Province / Northeast Iran
|
|
Name
|
| |
Reza Malekzadeh
|
|
Institution
|
| |
Digestive Disease Research Institute, Tehran University of Medical Sciences
|
|
Email
|
| |
dr.reza.malekzadeh@gmail.com
|
|
Do you want to add another Principal Investigator of the Cohort
|
| |
- Add another Principal Investigator of the cohort
|
|
Name
|
| |
Paul Brennan
|
|
Institution
|
| |
International Agency for Research on Cancer (IARC)
|
|
Email
|
| |
gep@iarc.fr
|
|
Do you want to add another Principal Investigator of the Cohort
|
| |
- Add another Principal Investigator of the cohort
|
|
Name
|
| |
Christian Abnet
|
|
Institution
|
| |
National Cancer Institute (NCI)
|
|
Email
|
| |
abnetc@mail.nih.gov
|
|
Name
|
| |
Mahdi Sheikh
|
|
Institution
|
| |
International Agency for Research on Cancer (IARC)
|
|
Email
|
| |
sheikhm@fellows.iarc.fr
|
|
Phone
|
| |
0033787121551
|
|
Website
|
| |
- https://dceg2.cancer.gov/gemshare/studies/GCS/
|
|
Name of committee
|
| |
International Agency for Research on Cancer (IARC) Ethics Committee / Digestive Diseases Research Institute Ethics Committee
|
|
Upload files
|
| |
|
|
Or provide website
|
| |
- https://en.ddri.ir/news/golestan-cohort-study
|
|
Contact Principal Investigator (name)
|
| |
Reza Malekzadeh
|
|
Data access policy (briefly describe)
|
| |
To access the data, first a proposal should be submitted to the cohort website which will be reviewd by the cohort reviewers and PIs. If the proposal is accepted the applicant will receive instructions on accessing the cohort data
|
|
Is this cohort part of a consortium? (name consortium)
|
| |
NCI Cohort Consortium / Asian Cohort Cobsortium / Internatioanl Hundred K+ Cohort Consortium
|
|
Main aim of cohort, please briefly describe the main objectives of the cohort
|
| |
The primary aims are: (i) To identify risk factors for oesophageal Cancer (OC) and other non communicable diseases by a comprehensive assessment of ethnicity, occupational history, socio-economic status, past medical history, family history of cancers, gastrointestinal symptoms and signs, tobacco, opium and alcohol use, oral health, anthropometric characteristics, physical activity and tea drinking habits, including tea temperature. Nutritional patterns are also evaluated using a food frequency questionnaire (FFQ) specifically developed for this population and validated during the pilot study.12 The FFQ covers 116 food items, including bread and cereals, meat and dairy products, oils, sweets, legumes, vegetables, fruits and condiments, as well as cooking methods. (ii) To establish biospecimen banks for blood, urine, hair and nail samples to be used in molecular and genetic studies of cross-sectional or nested case–control design. (iii) To provide a model for population-based studies in a country in economic and social transition based on collaboration between local health workers, local health authorities, national research centres, national government and international research institutions.
|
|
Study design (please select as many as appropriate)
|
| |
|
|
Source population (please select as many as appropriate)
|
| |
- General population: Regional
|
|
Inclusion criteria
|
| |
age between 40 - 75 years; permanent residence in the study area
|
|
Exclusion criteria
|
| |
Unwillingness to participate at any stage of the study for any reason; Being a temporary resident; Having a current or previous diagnosis of an upper gastrointestinal cancer
|
|
Enrollment
|
| |
Completed
|
|
Age range at entry (main cohort)
|
| |
| Minimum |
Maximum |
Mean |
| 40 |
75 |
52 |
|
|
Men at enrollment
|
| |
21234
|
|
Women at enrollment
|
| |
28811
|
|
Children (<18 years) at enrollment
|
| |
0
|
|
Men at last follow-up
|
| |
21073
|
|
Women at last follow-up
|
| |
28452
|
|
Children (<18 years) at last follow-up
|
| |
0
|
|
Participation rate at enrollment (if known)
|
| |
78
|
| 2. OUTCOME FOLLOW-UP |
|
Type of data for outcome follow-up (please select as many as appropriate)
|
| |
- Active (contact with participants)
- Death certificate
- Disease incidence records
- Hospital / physician diagnoses
- Use of registers (specify)
|
|
Active (contact with participants) (specify)
|
| |
- The participants have been followed since enrollment by annual telephone surveys and home visits. If participants or their families reported incident cancers or deaths a staff member was sent to the home of the patient or the deceased to collect detailed information, and then a team was sent to the corresponding medical centers to gather copies of relevant medical reports.
|
|
Death certificate (specify)
|
| |
- Death certificates were collected and reviewd by the cohort staff
|
|
Disease incidence records (specify)
|
| |
- If participants or their families reported incident cancers a staff member was sent to the home of the patient to collect detailed information, and then a team was sent to the corresponding medical centers to gather copies of relevant medical reports. Collected documents were separately reviewed by two expert physicians to verify the diagnosis of cancer. In case of disagreement, a third expert physician finalized the diagnosis.
|
|
Hospital / Physician diagnoses (specify)
|
| |
- In case of cancer diagnosis a team is sent to the corresponding medical center to gather copies of all relevant medical documents
|
|
Specify: Use of registers
|
| |
- Golestan Population-based Cancer Registry
|
|
First follow-up period (provide year)
|
| |
1 year after enrolment (2005)
|
|
Last follow-up period (provide year)
|
| |
Continued (2020)
|
|
Number of follow-ups after baseline (provide number)
|
| |
at least 12 follow-ups
|
|
Participation at last follow-up (if known)
|
| |
98
|
| 3. OCCUPATIONAL EXPOSURES |
|
Source of exposure data collected (please select as many as appropriate)
|
| |
- Questionnaire, Personal (Self-reporting or interview)
|
|
Occupational history/time frame
|
| |
Lifetime
|
|
Occupational coding performed
|
| |
No
|
|
Methods for exposure assessment (please select as many as appropriate)
|
| |
|
| 4. OUTCOMES EVALUATED |
|
Baseline - type of outcome data collected (select more than one if applicable)
|
| |
- Death certificates
- Medical records
- Questionnaire, individual (self-recording or interview)
- Registry-based
|
|
Registry-based
|
| |
|
|
Follow-up - type of outcome data collected (select more than one if applicable)
|
| |
- Death certificates
- Medical records
- Questionnaire, individual (self-recording or interview)
- Registry-based
|
|
Registry-based
|
| |
|
|
Outcome type (please select as many as appropriate)
|
| |
|
|
Diagnostic groups based on ICD10
|
| |
- C + D Neoplasms
- G Disease in the nervous system
- I Heart disease
- I Cerebrovascular diseases
- J Respiratory disease
- K Diseases of oesophagus, stomach, duodenum and appendix
- K Diseases of peritoneum, liver
- N Kidney, renal pelvis disease
|
|
C + D Neoplasms
|
| |
- Benign neoplasm
- Carcinoma in situ
- Leukemia
- Malignant neoplasms gastro intes. system including liver, gall bladder, pancreas
- Malignant neoplasm lung
- Mesothelioma
- Other malignant neoplasm of respiratory and intrathoracic organs, heart, pleura
- Malignant neoplasm of bone and articular cartilage
- Melanoma and other malignant neoplasms of skin
- Neoplasms connective and soft tissue including nerves
- Malignant neoplasm of breast
- Malignant neoplasms, females gynecological
- Malignant neoplasms of male genital organs
- Malignant neoplasm of urinary tract and kidney
- Malignant neoplasms of eye, brain and other parts of central nervous system
- Malignant neoplasms of thyroid and other endocrine glands
- Malignant neoplasms of ill-defined, secondary and unspecified sites
- Malignant neoplasm without specification of site including excl. leukemia
- Other, please state
|
|
I Heart disease
|
| |
- Angina pectoris
- Acute myocardial infarction
- Chronic ischaemic heart disease
|
|
I Cerebrovascular diseases
|
| |
- Stroke, not specified as haemorrhage or infarction
|
|
J Respiratory disease
|
| |
- Chronic obstructive pulmonary disease (COPD)
- Asthma
|
|
K Diseases of oesophagus, stomach, duodenum and appendix
|
| |
- Gastro-oesophageal reflux disease
- Gastric ulcer
- Dyspepsia
|
|
K Diseases of peritoneum, liver
|
| |
- Chronic hepatitis
- Fibrosis and cirrhosis of liver
|
|
N Kidney, renal pelvis disease
|
| |
|
| 5. BIOLOGICAL SAMPLES & ANALYSIS |
|
Biological samples collected
|
| |
|
